Sirona Biochem Corp V.SBM

Where is the bottom?

[hcdtrading]

.18 is in play which is the March low. I been thinking about jumping back into this steaming pile of you know what but want to see how good of a deal I can get. Maybe it goes on a move in the fall perhaps. I still question whether the R&F business model (how they do their sales) is going to be valid in this new covid era we are in now.  No one seems to want to touch this idea on here when I bring it up. Seriously though, are there gonna be house parties and tupperware style parties to sell this SH**?  door to door sales? I think R&F has to rethink how they get sales here because how they were successful before may not work going forward.

[skiboard09]

I think I'll leave R&Fs business plan up to them as they now have grown multiple multi billion dolllar companies.  regarding share price anything is possible at this point. Low volume, no promoting, no news= people losing interest and moving money into things that are actually rallying with the market.  howard once again has missed an amazing market rally and has said

[JohnFriesen]

This post has been removed in accordance with Community Policy

[forhandlaren]

I think that the doubt about R+F business model these days is valid. But I'm not very concerned about actual sales figures since I deem the objective of the deal is to get street cred for Sirona in order to show off to other players. I'm satisfied with a product on the market. Tick in the box. However, the challenge that the management has created is to convince other players to pay a

[hcdtrading]

I did say .18 was in play from my post on Aug 7. Looks like we will get there. Or should say you will get there as I have not bought back in yet. waiting for the bottom here. A thing to remember and people seem to forgot is that this is about investing your $$ and hopefully making money, the issue is so many get married to the company and the idea and hold on too long, it then becomes this

[skiboard09]

Why was Howard so worried about the share holder rights plan. Ever since then we have been declining in price substantially. What was the purpose?  No one seems to be buying us, when we can't even announce previous told deals.   

[JohnFriesen]

This post has been removed in accordance with Community Policy

[MRB403]

HCDTrading What are your thoughts now?

[MRB403]

I held on at 8 cents for years then missed the bought then got back in at 21 cents. Either way, sold for low gain, rode it up and rode it down. May missed the boat again but could lose any mroe money. Moved into V.KNR, last week. Great technology and potentially a bright future,  but so many big unknowns short term.

[forhandlaren]

I think the share price is closer to 25 cents than 18. Given that the management target list is valid a positive news release should not be too far away, maybe as soon as next week. I can only speculate, but since river_invest tweet still remains unanswered, the answer could be a news release instead of a tweet reply.

[Frosch1]

No answer on Twitter Share price under 20 cent Either the wait to release soon very good news or they are really desperate...

[24minus7]

...you forget to mention a third possibility, maybe the cat is dead too. Joking aside, a great newsflow is probably waiting for us soon. I'm very excited about the cat diabetes deal with my personal dream candidate Boehringer Ingelheim. This would probably also be the moment when we can expect an attractive upfront payment.

[MirrorWorldMan]

Any NR without numbers means there is no revenue

[wexworth]

Not true. Whether partnerships provide immediate or longer term revenue, the legal agreement itself can potentially have significant value to shareholders.

[MirrorWorldMan]

Sirona NR's without numbers attached have been observed to provide no revenue, increased dilution, increased liabilities and corroded Share Price. Their milestones are internal metrics only cost more money and without monetary objectives, there had been no revenue projections. Hence all NR's have meant no revenue and increased expenses 

[Pareto8020]

I think to get the stock moving they'll need a contract with some firm #'s attached.  None of this we can't divulge figures due to the big guys we are dealing with want privacy for competitive reasons.  Enough - land a contract that has some metrics that can be applied to SBM's shareprice.     Also they need a home run as far as size of those numbers. 

[wexworth]

There are all kinds of public companies that are worth billions without any or negligible revenue to support the valuation  - why? Because of two things: 1) they have the intellectual property to control the space, which is particularly important for those technologies that are differentiated and "game changing",  AND (not or) 2) they have access to infrastructure

[MRB403]

Well said, Wexworth! There is alot of potential with SBM, slow and steady wins the race. 

[MirrorWorldMan]

No numbers : No Share Price. The market is spooked with SBM promises and no revenue after so many years. 

[wexworth]

Ultimately you nor I really know how the market will react. Its really news and situation dependant.

[PutinKhuylo1]

To quote our infamous US congressman, Ozzie Myers, as he was being bribed by the FBI in the ABSCAM scandal sting operation: "Around here, money talks, BS walks." Bring on the deals, stock price will follow. SBM is dirt cheap right now.

[MirrorWorldMan]

Its dirt cheap for a reason. No revenue. All the self proclaimed best deals they can say will notchange anything anymore without income. None of their list of objectives had new income attaches. Funding for operations need to come from other sources besides more loans and increased dilution.  Its a steady incinerator for cash. 

[wexworth]

As with all junior biotech, the situation can change very very quickly, and so all that Putinkylo was pointing out was that for the value of the science, existing and potential future agreements and initiatives it is looking like the valuation is quite attractive. Many of the long term patient investors I believe agree with that.   

[MirrorWorldMan]

Surviving 8 years here and having possession of a significant chunk of this company places me in the Long Term investor group. Expecting results in response to previous repeated promises by Howie is not being impatient on my behalf. The point of reasonable expectations based on company rhetoric has been passed. Sirona is very disappointing, even as a small micro cap junior biotech. There are